{"preliminary_commentary":{"by_channel":{"youtube":6,"x_thread":5,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03145961\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"c-TRAK-TN","nct_id":"NCT03145961","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=c-trak-tn-nct03145961. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"c-TRAK-TN","arms":[{"description":"Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.","label":"Observation","type":"NO_INTERVENTION"},{"description":"Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.","label":"Pembrolizumab Treatment","type":"EXPERIMENTAL"}],"collaborators":["National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2024-03-31","type":"ESTIMATED"},"conditions":["Triple Negative Breast Cancer"],"enrollment":{"count":208,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2022-02-24","lead_sponsor":"Institute of Cancer Research, United Kingdom","official_title":"c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2021-09-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Positive ctDNA detection by 12 months","timeFrame":"12 months"},{"measure":"Positive ctDNA detection by 24 months","timeFrame":"24 months"},{"measure":"Absence of detectable ctDNA or disease recurrence 6 months (24 weeks) after commencing pembrolizumab","timeFrame":"6 months (24 weeks) after commencing pembrolizumab"}],"references":[{"citation":"Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson IR, Okines AFC, Palmieri C, Perry S, Randle K, Snowdon C, Stobart H, Wardley AM, Wheatley D, Waters S, Winter MC, Hubank M, Allen SD, Bliss JM; c-TRAK TN investigators. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2023 Feb;34(2):200-211. doi: 10.1016/j.annonc.2022.11.005. Epub 2022 Nov 22.","pmid":"36423745","type":"DERIVED"}],"start_date":{"date":"2017-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients","url":"https://clinicaltrials.gov/study/NCT03145961"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/c-trak-tn-nct03145961"}